Explore the latest news from Khondrion and its team.
December 4, 2015 - FOR IMMEDIATE RELEASE Khondrion reports successful outcome of KH176 Phase 1 Clinical trials NIJMEGEN – Khondrion, the...
Khondrion has received an Orphan Drug Designation from the European Commission of its frontrunner compound...
Khondrion receives Orphan Drug Designation for treatment of MELAS syndrome NIJMEGEN – Khondrion, the Dutch pharmaceutical company focusing on small...
NIJMEGEN – Khondrion, the Dutch biopharmaceutical company focusing on small molecule therapeutics for mitochondrial...
Former Kinesis Director Clinical Development Edwin Spaans appointed as Khondrion's Chief Medical Officer. NIJMEGEN –December 15, 2014 ‐ Khondrion,...
Published: 25 November 2014 Khondrion has received an Orphan Drug Designation from the FDA of its frontrunner compound KH176, in the treatment of...
Khondrion Welcomes Hans Schikan, Former Prosensa CEO, to Advisory Board August 10, 2015, NIJMEGEN – Khondrion, the Dutch...
